Hassan Won’t Jump Ship: Exec Vows To See Schering Through Turnaround
This article was originally published in The Pink Sheet Daily
Schering-Plough CEO Fred Hassan has no plans to leave the beleaguered company before his five-year turnaround "action agenda" is complete
You may also be interested in...
Surge of interest prompts US FDA to consider how to adjust feedback, including potentially creating a separate team to answer more basic questions.
When the closest you can get to US FDA staff is Webex, the meeting minutes and interactions with the review team project manager take on increased importance, consultants suggest during an Informa-sponsored webinar.
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.